Expertise in
40
conditions

Dr. Roger C. Inhorn

Oncology
Mainehealth Pen Bay Medical Center
6 Glen Cove Dr, 
Rockport, ME 
Offers Telehealth
Expertise in
40
conditions
Mainehealth Pen Bay Medical Center
6 Glen Cove Dr, 
Rockport, ME 

Overview

Roger Inhorn is an Oncologist practicing medicine in Rockport, Maine.

Dr. Inhorn is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Angiosarcoma, Neuroendocrine Tumor, Paget Disease of the Breast, and Richter Syndrome.

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 5 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in ME

Hospital Affiliations

Lincolnhealth
Mainehealth Maine Medical Center
Mainehealth Pen Bay Hospital
Mainehealth Waldo Hospital
Maine General Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Mainehealth Pen Bay Medical Center
6 Glen Cove Dr, Rockport, ME 04856

Additional Areas of Focus

Dr. Inhorn has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Adult Immune Thrombocytopenia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
View 4 Less Clinical Trials

5 Total Publications

Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).
Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).
Journal: NPJ precision oncology
Published: June 11, 2023
Similar Doctors
Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

Hematology & Oncology

329 Maine St # E101, 
Brunswick, ME 
 (47.3 miles away)
207-373-2266
Languages Spoken:
English
See accepted insurances

Peter Westervelt is an Oncologist practicing medicine in Brunswick, Maine. Dr. Westervelt is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Colonoscopy.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Office

33 Whiting Hill Rd Ste 21, 
Brewer, ME 
 (47.5 miles away)
207-973-7478
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Audrey Garrett is an Oncologist practicing medicine in Brewer, Maine. Dr. Garrett is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Angiosarcoma, Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration.

Expertise in
34
conditions
Expertise in
34
conditions
Referral may be required

Mainegeneral Health Associates

361 Old Belgrade Rd, 
Augusta, ME 
 (37.7 miles away)
207-621-6100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

George Polkinghorn is an Oncologist practicing medicine in Augusta, Maine. Dr. Polkinghorn is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Paget Disease of the Breast.

Frequently Asked Questions about Dr. Roger C. Inhorn

How do I make an appointment with Dr. Roger C. Inhorn?

You can book an appointment with Dr. Roger C. Inhorn by calling their office at 207-301-8969. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Roger C. Inhorn a top-rated expert for Angiosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Roger C. Inhorn is classified as an Distinguished expert for Angiosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Roger C. Inhorn specialize in?

While Dr. Roger C. Inhorn is a Oncology, they have specific expertise in Angiosarcoma, Neuroendocrine Tumor, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Roger C. Inhorn participate in research or clinical trials?

Yes. Dr. Roger C. Inhorn has published 5 articles and abstracts on conditions like Angiosarcoma. You can view a list of Dr. Roger C. Inhorn's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Roger C. Inhorn accept my insurance?

Dr. Roger C. Inhorn accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 207-301-8969 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Inhorn's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 103 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile